Prostate Cancer
Conditions
Keywords
Prostate cancer, Metastatic Castration Resistant Prostate Cancer, Abiraterone acetate, Prednisone, Zytiga
Brief summary
The purpose of this study is to demonstrate the safety and effectiveness of abiraterone acetate when co-administered with prednisone in patients with chemo-naive metastatic castration resistant prostate Cancer (mCRPC).
Detailed description
This is a multinational, multicenter, randomized (the study drug is assigned by chance), double-blind (neither physician nor patient knows the treatment that the patient receives), placebo-controlled (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial) study. All patients will be randomly assigned in a 1:1 ratio between the abiraterone acetate group (abiraterone acetate and prednisone) and the placebo group (placebo and prednisone). The study will consist of a screening phase (within 28 days prior randomization on Cycle 1, Day 1), a treatment phase (28-day cycles until disease progression), and a follow-up phase (all patients will be contacted for every 3 months up to Month 60, focusing primarily on survival status). Patients will receive either abiraterone acetate 1,000 mg daily and prednisone 5 mg twice daily or placebo and prednisone 5 mg twice daily.
Interventions
DRUGPlacebo and prednisone
Placebo: Form=tablet, route=oral. Four tablets daily on an empty stomach. Prednisone: Type=exact number, unit=mg, number=5, form=tablet, route=oral, twice daily.
DRUGAbiraterone acetate and prednisone
Abiraterone acetate: Type=exact number, unit=mg, number=250, form=tablet, route=oral. Four tablets daily on an empty stomach Prednisone: Type=exact number, unit=mg, number=5, form=tablet, route=oral, twice daily
Sponsors
Janssen Research & Development, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Has a confirmed diagnosis of adenocarcinoma of the prostate with evidence of metastatic disease * Prostate cancer progression documented by PSA progression or radiographic progression * Asymptomatic or mildly symptomatic from prostate cancer * Surgically or medically castrated, with testosterone levels of \<50 ng/dL * Previous anti-androgen therapy and progression after withdrawal * ECOG performance status score of 0 or 1 * If opiate analgesics for cancer-related pain, treatment must not be administered within 4 weeks of Cycle 1 Day 1 * If radiation therapy for treatment of the primary tumor is given, treatment must not be administered within 6 weeks of Cycle 1 Day 1 * If previously treated with ketoconazole for prostate cancer, duration of treatment must not be greater than 7 days * Life expectancy of at least 6 months
Exclusion criteria
* Active infection or other medical condition that would make prednisone (corticosteroid) use contraindicated * Any chronic medical condition requiring a higher dose of corticosteroid than 5 mg prednisone twice daily * Pathological finding consistent with small cell carcinoma of the prostate * Liver or visceral organ metastasis, brain metastasis, and other malignancy, except non-melanoma skin cancer, with a 30% probability of recurrence within 24 months * Prior cytotoxic chemotherapy or biologic therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC) * Radiation or radionuclide therapy for treatment of mCRPC * Uncontrolled hypertension, patients with a history of hypertension are allowed provided blood pressure is controlled by anti hypertensive treatment * History of pituitary or adrenal dysfunction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to prostate specific antigen (PSA) progression (TTPP) | 14 months | Measured from the time interval from the date of randomization to the date of the PSA progression based on prostate cancer clinical trials working group 2 (PCWG2) criteria |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to initiation of cytotoxic chemotherapy | 5 years | Date of randomization to date of initiation of chemotherapy |
| Prostate specific antigen (PSA) response rate | 14 months | Proportion of patients achieving a PSA decline 50% according to prostate cancer clinical trials working group 2 (PCWG2) criteria |
| Objective response rate | 14 months | Measurable disease based on modified response evaluation criteria in solid tumors (RECIST) criteria and baseline lymph node size must be 2.0 cm to be considered target or evaluable lesion for RECIST criteria |
| Overall survival | 5 years | The percentage of people in a study or treatment group who are alive from date of randomization to date of death |
| Time to pain progression | 14 months | Assessed by the Brief Pain Inventory Short Form (BPI-SF) and analgesic score |
| Time to Eastern Cooperative Oncology Group (ECOG) performance status score determination | 14 months | ECOG performance status score 0 (Fully active, able to carry on all pre-disease performance without restriction) versus 1 (Restricted in physically strenuous activity but ambulatory and able to carry out work on a light or sedentary nature, eg, light housework, office work) |
| Collection of safety data including adverse events | 5 years | — |
| Quality of life (QoL) total score and each subscale score | 14 months | Assessed by functional assessment of cancer therapy-prostate (FACT-P) |
Countries
China, Malaysia, Russia, Thailand
Outcome results
None listed